These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37442373)

  • 41. High-risk lineages among extended-spectrum β-lactamase-producing Escherichia coli from extraintestinal infections in Maputo Central Hospital, Mozambique.
    Santona A; Sumbana JJ; Fiamma M; Deligios M; Taviani E; Simbine SE; Zimba T; Sacarlal J; Rubino S; Paglietti B
    Int J Antimicrob Agents; 2022 Oct; 60(4):106649. PubMed ID: 35934230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular detection of plasmid mediated bla
    Chaudhary MK; Jadhav I; Banjara MR
    Ann Clin Microbiol Antimicrob; 2023 May; 22(1):33. PubMed ID: 37147617
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study.
    Meybeck A; Ricard JD; Barnaud G; Eveillard M; Chevrel G; Mounier R; Dreyfuss D
    BMC Infect Dis; 2008 May; 8():67. PubMed ID: 18485230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genotypic resistance determined by whole genome sequencing versus phenotypic resistance in 234 Escherichia coli isolates.
    Vanstokstraeten R; Piérard D; Crombé F; De Geyter D; Wybo I; Muyldermans A; Seyler L; Caljon B; Janssen T; Demuyser T
    Sci Rep; 2023 Jan; 13(1):449. PubMed ID: 36624272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. False extended-spectrum {beta}-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins.
    Beceiro A; Maharjan S; Gaulton T; Doumith M; Soares NC; Dhanji H; Warner M; Doyle M; Hickey M; Downie G; Bou G; Livermore DM; Woodford N
    J Antimicrob Chemother; 2011 Sep; 66(9):2006-10. PubMed ID: 21742679
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Escherichia coli clinical isolates.
    Sumi CD; Heffernan AJ; Naicker S; Cottrell K; Wallis SC; Lipman J; Harris PNA; Sime FB; Roberts JA
    J Antimicrob Chemother; 2022 Oct; 77(11):3026-3034. PubMed ID: 36031790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Whole genome sequences of multi-drug resistant Escherichia coli isolated in a Pastoralist Community of Western Uganda: Phylogenomic changes, virulence and resistant genes.
    Iramiot JS; Kajumbula H; Bazira J; de Villiers EP; Asiimwe BB
    PLoS One; 2020; 15(5):e0231852. PubMed ID: 32469885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study.
    Henderson A; Paterson DL; Chatfield MD; Tambyah PA; Lye DC; De PP; Lin RTP; Chew KL; Yin M; Lee TH; Yilmaz M; Cakmak R; Alenazi TH; Arabi YM; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj SS; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke DFM; Runnegar NJ; Miyakis S; Walls G; Khamis MAI; Zikri A; Crowe A; Ingram PR; Daneman N; Griffin P; Athan E; Roberts L; Beatson SA; Peleg AY; Cottrell K; Bauer MJ; Tan E; Chaw K; Nimmo GR; Harris-Brown T; Harris PNA;
    Clin Infect Dis; 2021 Dec; 73(11):e3842-e3850. PubMed ID: 33106863
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Are there differences between ceftolozane/tazobactam and ceftazidime/avibactam in treating patients with complicated abdominal infections? Evidence from clinical trials.
    Avilés Martínez MC; Alfaro Martínez JJ; Blanch Sancho JJ; Solís García Del Pozo J
    J Chemother; 2022 Nov; 34(7):419-426. PubMed ID: 35550007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.
    Rodríguez-Villodres Á; Ortiz de la Rosa JM; Álvarez-Marín R; Pachón J; Aznar J; Lepe JA; Smani Y
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061749
    [No Abstract]   [Full Text] [Related]  

  • 51. Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant
    Rodríguez Villodres A; Gálvez Benítez L; Arroyo MJ; Méndez G; Mancera L; Vila Domínguez A; Lepe Jímenez JA; Smani Y
    Emerg Microbes Infect; 2022 Dec; 11(1):2034-2044. PubMed ID: 35972021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible
    Han MS; Park KS; Jeon JH; Lee JK; Lee JH; Choi EH; Lee SH
    Microb Drug Resist; 2020 Apr; 26(4):334-340. PubMed ID: 31651221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of Piperacillin-Tazobactam ETEST for the Detection of OXA-1 Resistance Mechanism among Escherichia coli and Klebsiella pneumoniae.
    Manuel C; Maynard R; Humphries RM
    J Clin Microbiol; 2022 Dec; 60(12):e0143022. PubMed ID: 36416539
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
    Fujita A; Kimura K; Yokoyama S; Jin W; Wachino J; Yamada K; Suematsu H; Yamagishi Y; Mikamo H; Arakawa Y
    PLoS One; 2015; 10(11):e0142366. PubMed ID: 26539828
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
    J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36763081
    [No Abstract]   [Full Text] [Related]  

  • 57. Antibiotic trapping by plasmid-encoded CMY-2 β-lactamase combined with reduced outer membrane permeability as a mechanism of carbapenem resistance in Escherichia coli.
    Goessens WH; van der Bij AK; van Boxtel R; Pitout JD; van Ulsen P; Melles DC; Tommassen J
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3941-9. PubMed ID: 23733461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploring the genetic mechanisms underlying amoxicillin-clavulanate resistance in waterborne Escherichia coli.
    Singh NS; Singhal N; Kumar M; Virdi JS
    Infect Genet Evol; 2021 Jun; 90():104767. PubMed ID: 33581330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing
    Benanti GE; Brown ART; Shigle TL; Tarrand JJ; Bhatti MM; McDaneld PM; Shelburne SA; Aitken SL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509935
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae causing intra-abdominal infections from 9 tertiary hospitals in China.
    Liao K; Chen Y; Wang M; Guo P; Yang Q; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Hu Z; Chu Y; Chen S; Cao B; Su J; Gui B; Duan Q; Zhang S; Shao H; Kong H; Xu Y
    Diagn Microbiol Infect Dis; 2017 Jan; 87(1):45-48. PubMed ID: 27773544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.